Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757568 | 0.85 | IMPDH2 (0.46) | IMPDH2IMPDH1APPSLC6A2SLC6A4 | |
| SCHEMBL30375430 | 0.83 | LTA4H (0.51) | APPSLC6A4LTA4HCHRNB4CHRNA3 | |
| SCHEMBL30375754 | 0.83 | CHRNB4 (0.48) | APPLTA4HCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31757556 | 0.82 | CHRNB4 (0.47) | APPLTA4HCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31757553 | 0.80 | APP (0.45) | APPLTA4HCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31757537 | 0.80 | CHRNA7 (0.53) | APPLTA4HCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31757558 | 0.80 | APP (0.45) | APPLTA4HCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30375571 | 0.79 | CYP17A1 (0.58) | APPLTA4HCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30375972 | 0.78 | KCNH2 (0.48) | APPLTA4HCHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30233681 | 0.77 | MAOA (0.51) | APPSLC6A2SLC6A3LTA4HCHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | IMPDH2 3438/4885IMPDH1 3103/4885APP 1824/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | IMPDH2 1775/4885IMPDH1 1757/4885APP 1734/4885 |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | IMPDH2 1775/4885IMPDH1 1757/4885APP 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.